IMMX

Immix Biopharma, Inc. (IMMX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR-T) cell therapies, primarily for AL Amyloidosis. The company's lead candidate, NXC-201, holds FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased by approximately $1.43 million compared to the same period in 2024, driven by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses rose to $5.95 million (YTD 2025) from $5.47 million (YTD 2024). This increase is attributed to costs associated with the ongoing Phase 1b/2a clinical trial (NEXICART-2), including patient treatment, site onboarding, and license fees.
• G&A Expense Growth: G&A expenses increased to $5.45 million (YTD 2025) from $4.82 million (YTD 2024), primarily due to increased compensation from hiring additional employees and higher professional fees.
• Decline in Interest Income: Interest income dropped to $254,275 (YTD 2025) from $574,823 (YTD 2024) due to lower average cash balances invested in money market funds and US Treasuries.
• Cash Burn: Net cash used in operating activities was $6.99 million for the six months ended June 30, 2025, compared to $9.08 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has expressed substantial doubt regarding the company's ability to continue as a going concern for at least the next twelve months. Current cash resources ($11.6 million) are deemed insufficient to fund planned operations through that period without additional financing.
• Funding Strategy: The company is actively raising capital through an At-The-Market (ATM) offering agreement (up to $50 million) and relies on an $8 million grant from the California Institute for Regenerative Medicine (CIRM). As of June 30, 2025, $3.6 million of the CIRM grant had been received, with $4.4 million remaining contingent on milestones.
• Clinical Progress: The company expanded its NEXICART-2 clinical trial to 18 sites in July 2025. Recent data presented at ASCO 2025 showed a 100% overall response rate and 70% complete response rate in treated patients, with no observed neurotoxicity.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to a lack of segregation of duties and formal processes, resulting from its small size and limited personnel.
• License Obligations: The company has significant future payment obligations under license agreements with Hadasit and BIRAD, including quarterly payments totaling approximately $13.0 million through September 2026 and potential milestone payments.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of current cash ($11.6M) plus the remaining CIRM grant ($4.4M) against the projected burn rate to confirm the timeline for the next capital raise.
• ATM Utilization: Monitor the pace of share sales under the June 2025 ATM agreement and the resulting dilution to existing shareholders.
• CIRM Milestones: Confirm the specific patient enrollment milestones required to unlock the remaining $4.4 million in CIRM grant funding.
• License Payments: Review the schedule of upcoming quarterly license payments to Hadasit and BIRAD to assess near-term cash outflow requirements.
• Internal Control Remediation: Track the company's progress in remediating the material weakness in internal controls to ensure future financial reporting reliability.